AMRX
FDA Approves AMNEAL (AMRX) Generic of $983M Somatuline Depot, Launch Immediate
Amneal won FDA approval for lanreotide injection 120 mg/0.5 mL with Competitive Generic Therapy designation and is launching the product immediately.
AMRX
Market-moving news on Amneal Pharmaceuticals (NASDAQ: AMRX): filings, earnings, deals and other events, from REDFILED.